Myriad, Cephalon announce CDx agreement
SALT LAKE CITY—Myriad Genetics Inc. and Cephalon Inc., a subsidiary of Teva Pharmaceutical Industries Ltd. Co., have signed an agreement to conduct BRCA1 and BRCA2 mutation testing on patients that will be enrolled in a Phase I/II clinical study. Per the agreement, Myriad will determine the BRCA status of the patients utilizing its BRACAnalysis test prior to their enrollment in the study. Myriad's BRACAnalysis is a molecular diagnostic product capable of determining a woman's risk for hereditary breast and ovarian cancer.
"We are extremely pleased to be working with Cephalon, one of the world's leading healthcare companies, on this exciting new clinical study. This collaboration is a further demonstration of Myriad's commitment to and leadership in the field of companion diagnostics," Peter Meldrum, president and CEO of Myriad, said in a press release.